Brain amyloid-beta fragment signatures in pathological ageing and alzheimer's disease by hybrid immunoprecipitation mass spectrometry

Neurodegenerative Diseases

Volumn 15, Issue 1, 2015, Pages 50-57

  Portelius, Erik ^a   Lashley, Tammaryn ^b   Westerlund, Anni ^a   Persson, Rita ^a   Fox, Nick C ^d   Blennow, Kaj ^a   Revesz, Tamas ^b   Zetterberg, Henrik ^a,c  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b Queen Square Brain Bank   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; Amyloid precursor protein; Amyloid ; Brain; Immunoprecipitation; Mass spectrometry; Pathological ageing

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; FORMIC ACID; PYROGLUTAMIC ACID; BIOLOGICAL MARKER; PEPTIDE FRAGMENT;

ADULT; AGED; AGING; ALZHEIMER DISEASE; ARTICLE; BRAIN TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOPRECIPITATION; MALE; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MIDDLE AGED; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; PRIORITY JOURNAL; SENILE PLAQUE; TEMPORAL CORTEX; VERY ELDERLY; AMYLOID PLAQUE; AUTOPSY; COMPARATIVE STUDY; METABOLISM; PATHOLOGY; TEMPORAL LOBE;

AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AUTOPSY; BIOLOGICAL MARKERS; FEMALE; HUMANS; IMMUNOPRECIPITATION; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PLAQUE, AMYLOID; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TEMPORAL LOBE;

EID: 84924261797     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000369465     Document Type: Article

References (25)

1. Blennow K, De Leon MJ, Zetterberg H: Alzheimers disease. Lancet 2006; 368: 387-403
2. Walsh DM, Teplow DB: Alzheimers disease and the amyloid beta-protein. Prog Mol Biol Transl Sci 2012; 107: 101-124
3. Wasling P, Daborg J, Riebe I, AnDersson M, Portelius E, Blennow K, Hanse E, Zetterberg H: Synaptic retrogenesis and amyloid-beta in Alzheimers disease. J Alzheimers Dis 2009; 16: 1-14
4. Jucker M, Walker LC: Pathogenic protein seeding in Alzheimer disease and other neuroDegenerative disorDers. Ann Neurol 2011; 70: 532-540
5. Walsh DM, Selkoe DJ: A oligomers-A DecaDe of discovery. J Neurochem 2007; 101: 1172-1184
6. Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C: Age, neuropathology, and Dementia. N Engl J Med 2009; 360: 2302-2309
7. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ: Hypothetical moDel of dynamic biomarkers of the Alzheimers pathological cascaDe. Lancet Neurol 2010; 9: 119-128
8. Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O: Cerebrospinal fluid levels of beta-Amyloid 1-42, but not of tau, are fully changed already 5-10 years before the onset of Alzheimer Dementia. Arch Gen Psychiatry 2012; 69: 98-106
9. Moghekar A, Li S, Lu Y, Li M, Wang MC, Albert M, OBrien R: CSF biomarker changes preceDe symptom onset of mild cognitive impairment. Neurology 2013; 81: 1753-1758
10. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, MoulDer K, Aisen PS, Ghetti B, Klunk WE, McDaDe E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC: Clinical and biomarker changes in dominantly inherited Alzheimers disease. N Engl J Med 2012; 367: 795-804
11. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K: Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A 1985; 82: 4245-4249
12. Miller DL, Papayannopoulos IA, Styles J, Bobin SA, Lin YY, Biemann K, Iqbal K: PeptiDe compositions of the cerebrovascular and senile plaque core amyloid Deposits of Alzheimers disease. Arch Biochem Biophys 1993; 301: 41-52
13. Portelius E, Bogdanovic N, Gustavsson MK, Volkmann I, Brinkmalm G, Zetterberg H, Winblad B, Blennow K: Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimers disease. Acta Neuropathol 2010; 120: 185-193
14. Moore BD, Chakrabarty P, Levites Y, Kukar TL, Baine AM, Moroni T, Ladd TB, Das P, Dickson DW, GolDe TE: Overlapping profiles of A peptiDes in the Alzheimers disease and pathological aging brains. Alzheimers Res Ther 2012; 4: 18
15. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimers disease. Report of the NINCDS-ADRDA Work Group unDer the auspices of Department of Health and Human Services Task Force on Alzheimers Disease. Neurology 1984; 34: 939-944
16. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, Van Belle G, Berg L: The consortium to establish a registry for Alzheimers disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimers disease. Neurology 1991; 41: 479-486
17. Thal DR, Rub U, Orantes M, Braak H: Phases of a beta-Deposition in the human brain and its releVance for the Development of AD. Neurology 2002; 58: 1791-1800
18. Lashley T, Holton JL, Gray E, Kirkham K, OSulliVan SS, Hilbig A, Wood NW, Lees AJ, Revesz T: Cortical alpha-synuclein load is associated with amyloid-beta plaque burDen in a subset of Parkinsons disease patients. Acta Neuropathol 2008; 115: 417-425
19. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K: Staging of Alzheimer disease-Associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 2006; 112: 389-404
20. Portelius E, Tran AJ, Andreasson U, Persson R, Brinkmalm G, Zetterberg H, Blennow K, Westman-Brinkmalm A: Characterization of amyloid beta peptiDes in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. J Proteome Res 2007; 6: 4433-4439
21. Mattsson N, Rajendran L, Zetterberg H, Gustavsson M, Andreasson U, Olsson M, Brinkmalm G, Lundkvist J, Jacobson LH, Perrot L, Neumann U, Borghys H, Mercken M, Dhuyvetter D, Jeppsson F, Blennow K, Portelius E: BACE1 inhibition induces a specific cerebrospinal fluid beta-Amyloid pattern that iDentifies drug effects in the central nervous system. PLoS One 2012; 7:e31084
22. Pike CJ, Overman MJ, Cotman CW: Aminoterminal Deletions enhance aggregation of beta-Amyloid peptiDes in vitro. J Biol Chem 1995; 270: 23895-23898
23. Russo C, Violani E, Salis S, Venezia V, Dolcini V, Damonte G, Benatti U, DArrigo C, Patrone E, Carlo P, Schettini G: Pyroglutamate-modified amyloid beta-peptiDes-AN3(pE)-strongly affect cultured neuron and astrocyte survival. J Neurochem 2002; 82: 1480-1489
24. Bouter Y, Dietrich K, Wittnam JL, Rezaei-Ghaleh N, Pillot T, Papot-Couturier S, Lefebvre T, Sprenger F, Wirths O, Zweckstetter M, Bayer TA: N-truncated amyloid beta (A) 4-42 forms stable aggregates and induces acute and long-lasting behavioral Deficits. Acta Neuropathol 2013; 126: 189-205
25. Bayer TA, Wirths O: Focusing the amyloid cascaDe hypothesis on N-truncated A peptiDes as drug targets against Alzheimers disease. Acta Neuropathol 2014; 127: 787-801